{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:28:23Z","timestamp":1783117703083,"version":"3.54.6"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":189,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009610","name":"Pontificia Universidad Cat\u00f3lica de Chile","doi-asserted-by":"publisher","award":["200513023"],"award-info":[{"award-number":["200513023"]}],"id":[{"id":"10.13039\/501100009610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["FONDAP 152220002"],"award-info":[{"award-number":["FONDAP 152220002"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1180798"],"award-info":[{"award-number":["1180798"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1190156"],"award-info":[{"award-number":["1190156"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1230102"],"award-info":[{"award-number":["1230102"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["3220310"],"award-info":[{"award-number":["3220310"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1211547"],"award-info":[{"award-number":["1211547"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020266","name":"Ministerio de Ciencia, Tecnolog\u00eda, Conocimiento e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["ICN2021_045"],"award-info":[{"award-number":["ICN2021_045"]}],"id":[{"id":"10.13039\/100020266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020884","name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo","doi-asserted-by":"publisher","award":["COVID0920"],"award-info":[{"award-number":["COVID0920"]}],"id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Microbial Sciences"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.crmicr.2025.100440","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T22:35:41Z","timestamp":1752618941000},"page":"100440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Convalescent plasma therapy and long-term SARS-COV-2 antiviral immune response in a prospective cohort of patients with COVID-19"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2989-0275","authenticated-orcid":false,"given":"Aldo","family":"Barrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2836-9817","authenticated-orcid":false,"given":"Constanza","family":"Mart\u00ednez-Valdebenito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Nervi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aracelly","family":"Gaete-Argel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s M.S.","family":"G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Osses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Vizcaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda E.","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayling","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Mondaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Henr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis M.","family":"Kalergis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Soto-Rifo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Valiente-Echeverr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Ferres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda E.","family":"Balcells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9361-4049","authenticated-orcid":false,"given":"Nicole Le","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crmicr.2025.100440_bib0001","first-page":"m4232","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.crmicr.2025.100440_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102598","article-title":"COVID-19 convalescent plasma composition and immunological effects in severe patients","volume":"118","author":"Acosta-Ampudia","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.crmicr.2025.100440_bib0003","doi-asserted-by":"crossref","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.crmicr.2025.100440_bib0004","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia","volume":"22","author":"Arabi","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.crmicr.2025.100440_bib0005","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1186\/s12879-021-06829-7","article-title":"Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials","volume":"21","author":"Axfors","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.crmicr.2025.100440_bib0010","unstructured":"Bhimraj A.M.R, Shumaker A.H., Baden L., Cheng V.C., Edwards K.M., Gallagher J.C., Gandhi R.T., Muller W.J., Nakamura M.M., O'Horo J.C., Shafer R.W., Shoham S., Murad M.H., Mustafa R.A., Sultan S., Falck-Ytter Y., 2022. Infectious Diseases Society of America Guidelines on the Treatment and Management of patients with COVID-19. Infectious Diseases Society of America. Version 11.0.0. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/ (accessed 16 October 2023)."},{"key":"10.1016\/j.crmicr.2025.100440_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003415","article-title":"Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial","volume":"18","author":"Balcells","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.crmicr.2025.100440_bib0007","article-title":"SARS-CoV-2 infectivity and antigenic evasion: spotlight on isolated Omicron sub-lineages","volume":"11","author":"Barrera","year":"2024","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.crmicr.2025.100440_bib0008","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41591-021-01488-2","article-title":"Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial","volume":"27","author":"Begin","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.crmicr.2025.100440_bib0009","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe6855","article-title":"Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile","volume":"7","author":"Beltran-Pavez","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.crmicr.2025.100440_bib0011","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/cid\/ciad066","article-title":"Guidance on the use of convalescent plasma to treat immunocompromised patients with coronavirus disease 2019","volume":"76","author":"Bloch","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.crmicr.2025.100440_bib0025","unstructured":"COVID-19 Treatment Guidelines Panel, 2024. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https:\/\/www.covid19treatmentguidelines.nih.gov\/ (accessed 16 October 2023)."},{"key":"10.1016\/j.crmicr.2025.100440_bib0012","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17476348.2023.2208349","article-title":"Convalescent plasma therapy in COVID-19: unravelling the data using the principles of antibody therapy","volume":"17","author":"Casadevall","year":"2023","journal-title":"Expert. Rev. Respir. Med."},{"key":"10.1016\/j.crmicr.2025.100440_bib0013","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41375-023-01938-5","article-title":"Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)","volume":"37","author":"Cesaro","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.crmicr.2025.100440_bib0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.crmicr.2025.100440_bib0015","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science (1979)"},{"key":"10.1016\/j.crmicr.2025.100440_bib0016","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1056\/NEJMc2214293","article-title":"Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent Booster","volume":"388","author":"Davis-Gardner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.crmicr.2025.100440_bib0017","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1186\/s12879-021-06981-0","article-title":"Immunological effects of convalescent plasma therapy for coronavirus: a scoping review","volume":"21","author":"Esmaeili","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.crmicr.2025.100440_bib0018","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1038\/s41467-021-25312-0","article-title":"Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery","volume":"12","author":"Feng","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.crmicr.2025.100440_bib0019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tracli.2015.12.003","article-title":"Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow","volume":"23","author":"Garraud","year":"2016","journal-title":"Transfus. Clin. Biol."},{"key":"10.1016\/j.crmicr.2025.100440_bib0020","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1038\/s41467-021-23469-2","article-title":"Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection","volume":"12","author":"Gharbharan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.crmicr.2025.100440_bib0021","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","article-title":"A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2","volume":"27","author":"Grifoni","year":"2020","journal-title":"Cell Host. Microbe"},{"key":"10.1016\/j.crmicr.2025.100440_bib0022","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","author":"Group","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.crmicr.2025.100440_bib0023","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/s41590-020-0773-7","article-title":"ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection","volume":"21","author":"Hachim","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.crmicr.2025.100440_bib0024","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc2206576","article-title":"Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5","volume":"387","author":"Hachmann","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.crmicr.2025.100440_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001265","article-title":"The landscape of antibody binding in SARS-CoV-2 infection","volume":"19","author":"Heffron","year":"2021","journal-title":"PLoS Biol."},{"key":"10.1016\/j.crmicr.2025.100440_bib0027","article-title":"Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy","volume":"3","author":"Herman","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.crmicr.2025.100440_bib0028","article-title":"Convalescent plasma for people with COVID-19: a living systematic review","volume":"2","author":"Iannizzi","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.crmicr.2025.100440_bib0029","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-3083.2010.02432.x","article-title":"Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation","volume":"72","author":"Jager","year":"2010","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.crmicr.2025.100440_bib0030","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.crmicr.2025.100440_bib0031","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.crmicr.2025.100440_bib0032","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41467-021-27674-x","article-title":"Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts","volume":"13","author":"Kundu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.crmicr.2025.100440_bib0033","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.crmicr.2025.100440_bib0034","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1002\/jmv.26840","article-title":"SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma","volume":"93","author":"Lindemann","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.crmicr.2025.100440_bib0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.crmicr.2025.100440_bib0036","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167890","article-title":"COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response","volume":"8","author":"McDyer","year":"2023","journal-title":"JCI Insight."},{"key":"10.1016\/j.crmicr.2025.100440_bib0037","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.jaip.2020.06.046","article-title":"Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma","volume":"8","author":"Mira","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.crmicr.2025.100440_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103680","article-title":"COVID 19 convalescent plasma: is there still a place for CCP?","volume":"62","author":"Moog","year":"2023","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.crmicr.2025.100440_bib0039","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.crmicr.2025.100440_bib0040","article-title":"Outcomes of COVID-19 adults managed in an outpatient versus hospital setting","volume":"17","author":"Nguyen","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.crmicr.2025.100440_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/v13010026","article-title":"Peripheral blood immune profiling of convalescent plasma donors reveals alterations in specific immune subpopulations even at 2 months post SARS-CoV-2 infection","volume":"13","author":"Orologas-Stavrou","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.crmicr.2025.100440_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.12.002","article-title":"PD-1-expressing SARS-CoV-2-specific CD8(+) T cells are not exhausted, but functional in patients with COVID-19","volume":"54","author":"Rha","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.crmicr.2025.100440_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.03.018","article-title":"Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity","volume":"185","author":"Rodda","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.crmicr.2025.100440_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: possible mechanisms of action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.crmicr.2025.100440_bib0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.crmicr.2025.100440_bib0046","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis","volume":"6","author":"Senefeld","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.crmicr.2025.100440_bib0047","doi-asserted-by":"crossref","DOI":"10.1038\/d41591-020-00019-9","article-title":"15 drugs being tested to treat COVID-19 and how they would work","author":"Shaffer","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.crmicr.2025.100440_bib0048","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bjh.17272","article-title":"Early mortality benefit with COVID-19 convalescent plasma: a matched control study","volume":"192","author":"Shenoy","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.crmicr.2025.100440_bib0049","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in Covid-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.crmicr.2025.100440_bib0050","doi-asserted-by":"crossref","first-page":"m1256","DOI":"10.1136\/bmj.m1256","article-title":"Covid-19: FDA approves use of convalescent plasma to treat critically ill patients","volume":"368","author":"Tanne","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.crmicr.2025.100440_bib0051","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14055","article-title":"High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge","volume":"25","author":"Tayyar","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.crmicr.2025.100440_bib0052","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3851\/IMP2875","article-title":"A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus","volume":"20","author":"Vial","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.crmicr.2025.100440_bib0053","first-page":"1227","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science (1979)"},{"key":"10.1016\/j.crmicr.2025.100440_bib0054","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41423-021-00708-6","article-title":"Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.crmicr.2025.100440_bib0055","unstructured":"World Health Organization, 2024. WHO Coronavirus (COVID\u201119) Dashboard. https:\/\/covid19.who.int\/ (accessed 04 February 2024)."},{"key":"10.1016\/j.crmicr.2025.100440_bib0056","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/vox.12927","article-title":"Pivotal role of convalescent plasma in managing emerging infectious diseases","volume":"115","author":"Wong","year":"2020","journal-title":"Vox. Sang."},{"key":"10.1016\/j.crmicr.2025.100440_bib0057","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"326","author":"Estcourt","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.crmicr.2025.100440_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.708523","article-title":"Declining levels of neutralizing antibodies against SARS-CoV-2 in convalescent COVID-19 patients one year post symptom onset","volume":"12","author":"Xiang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmicr.2025.100440_bib0059","article-title":"Neutralizing antibodies and cellular immune responses against SARS-CoV-2 sustained one and a half years after natural infection","volume":"12","author":"Yan","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.crmicr.2025.100440_bib0060","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.crmicr.2025.100440_bib0061","article-title":"One-year sustained cellular and humoral immunities of COVID-19 convalescents","author":"Zhang","year":"2021","journal-title":"Clin. Infect. Dis."}],"container-title":["Current Research in Microbial Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666517425001014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666517425001014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:38:58Z","timestamp":1778920738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666517425001014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":61,"alternative-id":["S2666517425001014"],"URL":"https:\/\/doi.org\/10.1016\/j.crmicr.2025.100440","relation":{},"ISSN":["2666-5174"],"issn-type":[{"value":"2666-5174","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Convalescent plasma therapy and long-term SARS-COV-2 antiviral immune response in a prospective cohort of patients with COVID-19","name":"articletitle","label":"Article Title"},{"value":"Current Research in Microbial Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crmicr.2025.100440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100440"}}